Brian I. Rini, MD | Authors

Articles

Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC

October 26, 2018

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.

Rationale for Combining Atezolizumab/Bevacizumab in mRCC

July 16, 2018

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the IMmotion151trial.